Exelixis Inc

EXEL

$21.84

-7.4% (1 year change)

Market Cap

$6.88 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$16.19 - $25.77

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

73.17x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $6.88 Billion
Enterprise Value $5.53 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return -7.4%
52-Week High $25.77
52-Week Low $16.19
Beta 0.8
Outstanding Shares 315 Million
Avg 30 Day Volume 1.6 Million

Valuation

P/E Ratio 73.17
PEG 167.03
Earnings per Share $0.29
Price to Sales Ratio 7.28
Price to Book Ratio 3.64
Revenue to Enterprise Value 4.78
EBIT to Enterprise Value 55.28
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $1.16 Billion
Gross Profit $1.11 Billion
EBIT $100 Million
Net Income $94 Million
Profit Margin 8.13%
Quarterly Earnings Growth (YoY) +43.8%
Return on Equity 4.6%
Return on Assets 3.97%
Return on Invested Capital 4.74%

Insider trades

No purchases

234,097 shares sold (5 transactions)

No purchases

149,557 shares sold (7 transactions)

No purchases

115,000 shares sold (2 transactions)

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

Similar stocks

Glaxosmithkline plc - ADR
Sanofi - ADR
Merck & Co Inc
AMGEN Inc.
Johnson & Johnson
Pfizer Inc.
Curis Inc
AVEO Pharmaceuticals Inc

News

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkins Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkins Lymphoma

Kwhen Finance Kwhen Finance, 5 days ago
Exelixis Inc. (NASDAQ: EXEL) stock coverage initiated by Jefferies

Exelixis Inc. (NASDAQ: EXEL) stock coverage initiated by Jefferies

Exelixis Inc. (NASDAQ: EXEL) stock fell 1.08% (As on Oct 8, 12:34:50 AM UTC-4, Source: Google Finance) though Jefferies has started coverage with a Buy The post Exelixis Inc. (NASDAQ: EXEL) stock c...

FXDailyReport FXDailyReport, 10 days ago
Cancer API Market Giants Spending Is Going To Boom | Exelixis,Pfizer, AbbVie, Bayer

Cancer API Market Giants Spending Is Going To Boom | Exelixis,Pfizer, AbbVie, Bayer

Cancer Active Pharmaceuticals Drugs (API) is the ingredient in medical drug use for cancer. Cancer is unregulated and disordered cell development. There are five main API molecule categories includ...

OpenPR OpenPR, 13 days ago